This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Melanoma in situ of ear and external auricular canal
CD2_INSITU_MELANOMA_EAR_EXALLC
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
|
1. Apply sex-specific ruleNone |
- |
2. Check conditionsNone |
|
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
- |
4. Check minimum number of eventsNone |
- |
5. Include endpointsNone |
- |
6. Filter based on genotype QC (FinnGen only)None |
- |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D03
- Name in latin
- Melanoma in situ auriculae
Similar endpoints
↥List of similar endpoints to
Melanoma in situ of ear and external auricular canal
based on the number of shared cases.
Similar with more cases:
- Melanoma in situ of ear and external auricular canal
- Melanoma in situ
- Melanoma in situ
- Malignant melanoma
- Malignant melanoma, excluding all cancers (controls excluding all cancers)
Similar with less cases:
Case counts by codes
↥FinnGen case counts by registry codes:
No upset plot: script not run.
No upset table: script not run.
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 32 | 15 | 17 |
| Unadjusted period prevalence (%) | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | 70.36 | 67.31 | 73.04 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
No data available
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
unit
cases
controls
-log10(p)
N cases
N controls
(3002256) Pathology report gross observation
20
18
27.96
21.04
1.5
1.1
—
—
—
0
0
(40768804) Tissue Pathology biopsy report
25
70
12.64
9.53
4.2
1.6
—
—
—
0
0
(4035726)
10
5
27.91
7.69
1.5
1.0
—
—
—
0
0
(40768443) Skin Pathology biopsy report
8
13
7.78
3.77
1.0
1.3
—
—
—
0
0
(3022145) Colonoscopy Study observation
9
20
5.82
3.42
1.3
1.2
—
—
—
0
0
(42870588) Differential panel, method unspecified - Blood
18
81
3.79
3.34
5.6
6.0
—
—
—
0
0
(3022096) Basophils/100 leukocytes in Blood
21
106
3.85
3.26
6.1
6.0
%
0.7
0.6
0.26
21
98
(3019069) Monocytes/100 leukocytes in Blood
21
108
3.75
3.13
6.1
6.3
%
9.4
8.7
0.59
21
101
(3018010) Neutrophils/100 leukocytes in Blood
21
110
3.64
3.01
6.4
5.8
%
58.1
58.6
0.06
21
104
(3019198) Lymphocytes [#/volume] in Blood
21
123
3.06
2.28
6.4
5.3
e9/l
1.7
1.7
0.21
15
108
(40762366) Oxygen capacity [Volume Fraction] in Arterial blood
5
10
5.69
2.15
11.2
6.8
—
—
—
0
0
(36031861) Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection
6
17
4.09
1.94
1.3
1.8
—
—
—
0
0
(3006923) Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
32
274
+∞
1.89
10.3
9.4
u/l
22.9
24.1
0.20
32
262
(3014218) Bicarbonate [Moles/volume] standard in Arterial blood
5
15
3.74
1.58
12.0
7.4
mmol/l
24.2
26.0
—
5
10
(3014007) Fractional oxyhemoglobin in Arterial blood
5
15
3.74
1.58
13.0
7.1
%
92.0
89.1
—
5
15
(3006217) Methemoglobin/Hemoglobin.total in Arterial blood
5
16
3.50
1.50
12.2
6.6
%
0.4
0.7
—
5
16
(3028653) Carboxyhemoglobin/Hemoglobin.total in Arterial blood
5
17
3.28
1.41
13.0
6.5
%
1.3
2.0
—
5
17
(3000494) Fungus identified in Specimen by Culture
6
25
2.71
1.31
1.3
1.9
—
—
—
0
0
(3035941) MCH [Entitic mass]
32
285
+∞
1.24
20.7
20.5
pg
30.6
30.5
0.20
32
278
(3000963) Hemoglobin [Mass/volume] in Blood
32
285
+∞
1.24
21.2
20.7
g/l
135.9
135.3
0.08
32
278
(3024731) MCV [Entitic volume]
32
284
+∞
1.23
21.1
20.6
fl
91.9
91.5
0.22
32
277
(3000991) Gas panel - Venous blood
5
20
2.77
1.20
13.4
12.1
—
—
—
0
0
(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
7
37
2.14
1.01
1.3
1.9
—
—
—
0
0
(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
17
117
1.97
1.00
1.9
2.2
—
—
—
0
0
(3021589) Normoblasts [#/volume] in Blood
17
119
1.91
0.94
10.6
8.5
e9/l
0.0
0.0
0.00
12
98
(3019225) pH of Specimen
6
30
2.22
0.92
3.7
3.8
—
—
—
0
0
(46236098) ABO and Rh group [Type] in Blood by Confirmatory method
10
59
2.01
0.88
1.4
2.2
—
—
—
0
0
(40758558) Short blood count panel - Blood
9
56
1.84
0.82
4.4
5.4
—
—
—
0
0
(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip
6
102
0.49
0.80
2.2
4.3
—
—
—
0
0
(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
5
26
2.09
0.74
1.4
1.8
—
—
—
0
0
(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
5
27
2.00
0.72
1.4
1.7
—
—
—
0
0
(3044640) Blood type and Crossmatch panel - Blood
12
82
1.74
0.67
1.5
2.1
—
—
—
0
0
(43054903) Holo-transcobalamin II [Moles/volume] in Serum
16
119
1.69
0.66
2.3
2.1
pmol/l
126.0
95.1
—
7
61
(3019060) Gas panel - Arterial blood
0
21
0.00
0.62
0.0
2.6
—
—
—
0
0
(3048773) Triglyceride [Moles/volume] in Serum or Plasma --fasting
27
240
1.80
0.55
3.6
4.6
mmol/l
1.0
1.3
3.24
27
213
(3015736) pH of Urine
8
109
0.65
0.48
2.1
3.4
—
—
—
0
0
(3003396) Base excess in Arterial blood by calculation
5
32
1.66
0.44
13.0
4.9
mmol/l
-0.4
2.2
—
5
25
(3013512) EKG study
13
100
1.51
0.42
3.2
4.3
—
—
—
0
0
(4034850)
0
15
0.00
0.42
0.0
9.5
—
—
—
0
0
(36660697) Celiac disease serology panel - Serum
0
18
0.00
0.41
0.0
1.1
—
—
—
0
0
(36304419) Bacteria [Presence] in Urine
8
62
1.39
0.31
2.1
3.2
—
—
—
0
0
(3021337) Troponin I.cardiac [Mass/volume] in Serum or Plasma
8
62
1.39
0.31
5.6
3.3
ng/l
281.9
22.6
—
8
51
(3041096) Erythrocytes [Presence] in Urine by Automated
5
71
0.65
0.30
1.6
4.5
—
—
—
0
0
(3026008) Bacteria identified in Urine by Culture
8
101
0.72
0.26
1.9
2.9
—
—
—
0
0
(3009542) Hematocrit [Volume Fraction] of Blood
24
220
1.36
0.26
23.0
16.3
%
41.1
38.7
1.06
19
129
(3001079) Blood group antibody screen [Presence] in Serum or Plasma
14
119
1.31
0.23
2.1
4.0
—
—
—
0
0
(3037467) Urinalysis macro (dipstick) panel - Urine
21
189
1.32
0.23
3.0
4.6
—
—
—
0
0
(3005702) Mycobacterium sp identified in Specimen by Organism specific culture
0
11
0.00
0.22
0.0
1.2
—
—
—
0
0
(3015235) Bicarbonate [Moles/volume] in Capillary blood
0
11
0.00
0.22
0.0
1.5
—
23.8
—
0
6
(3022313) Gas panel - Capillary blood
0
10
0.00
0.22
0.0
3.8
—
—
—
0
0
(3046870) Tissue transglutaminase IgG Ab [Units/volume] in Serum
0
10
0.00
0.22
0.0
1.1
—
—
—
0
0
(3033705) Calcium.ionized [Moles/volume] in Venous blood
0
10
0.00
0.22
0.0
2.4
—
—
—
0
0
(3035285) Chloride [Moles/volume] in Venous blood
0
10
0.00
0.22
0.0
2.4
—
106.4
—
0
10
(3041354) Potassium [Moles/volume] in Venous blood
0
10
0.00
0.22
0.0
2.4
—
4.1
—
0
10
(3018405) Lactate [Moles/volume] in Arterial blood
0
12
0.00
0.21
0.0
2.1
—
1.1
—
0
12
(3051552) Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
(3007778) Kappa light chains/Lambda light chains [Mass Ratio] in Serum
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
(3003510) Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection
0
12
0.00
0.21
0.0
1.7
—
—
—
0
0
(3018095) Leukocytes [#/volume] in Urine
11
91
1.32
0.21
2.4
3.8
e6/l
5.3
38.7
—
5
65
(3024950) Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection
0
13
0.00
0.21
0.0
2.1
—
—
—
0
0
(3020891) Body temperature
0
13
0.00
0.21
0.0
2.8
—
—
—
0
0
(586526) SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection
0
13
0.00
0.21
0.0
1.5
—
—
—
0
0
(1761482) Bacteria [#/volume] in Urine by Culture
0
14
0.00
0.20
0.0
5.6
—
—
—
0
0
(3050449) Albumin [Mass/time] in Urine collected for unspecified duration
0
14
0.00
0.20
0.0
1.6
—
114.9
—
0
8
(3023602) Cholesterol in HDL [Moles/volume] in Serum or Plasma
27
254
1.40
0.19
4.1
5.0
mmol/l
1.5
1.4
0.48
27
227
(3023368) Bacteria identified in Blood by Culture
6
76
0.74
0.18
4.8
4.3
—
—
—
0
0
(1761868) Lipid panel - Serum or Plasma
6
72
0.80
0.08
2.0
4.2
—
—
—
0
0
(3002385) Erythrocyte distribution width [Ratio]
22
213
1.11
0.02
22.6
17.6
%
13.3
13.6
0.89
22
206
(3044889) 12 lead EKG panel
19
184
1.08
0.01
3.7
4.0
—
—
—
0
0
(3013707) Erythrocyte sedimentation rate by Westergren method
20
204
0.95
0.00
3.5
4.8
mm/h
10.3
12.6
0.42
20
184
(40760892) CBC W Ordered Manual Differential panel - Blood
5
52
0.95
0.00
2.6
4.3
—
—
—
0
0
(3013721) Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
8
84
0.94
0.00
2.3
2.6
u/l
30.1
28.1
—
8
79
(3003694) ABO and Rh group [Type] in Blood
6
67
0.87
0.00
1.2
1.3
—
—
—
0
0
(3010566) Parathyrin.intact [Moles/volume] in Serum or Plasma
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
(40762485) Glomerular basement membrane Ab [Units/volume] in Serum by Immunoassay
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
(3023419) Bacteria identified in Sputum by Culture
0
6
0.00
0.00
0.0
2.7
—
—
—
0
0
(3033319) Streptococcus pyogenes Ag [Presence] in Throat
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
(3050238) Crystals [Presence] in Synovial fluid by Light microscopy
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
(3043362) Influenza virus B Ag [Presence] in Nasopharynx by Immunoassay
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
(21494890) Protein electrophoresis panel - 24 hour Urine
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(3008909) Norovirus RNA [Presence] in Stool by NAA with probe detection
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
(3021584) Pregnancy associated plasma protein A [Units/volume] in Serum or Plasma
0
9
0.00
0.00
0.0
1.3
—
—
—
0
0
(43055120) Cytomegalovirus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
(3004248) Sex hormone binding globulin [Moles/volume] in Serum or Plasma
0
9
0.00
0.00
0.0
1.6
—
36.1
—
0
9
(3050129) First trimester maternal screen panel - Serum or Plasma
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count
9
94
0.94
0.00
2.1
3.2
—
—
—
0
0
(40760888) Immunoglobulin light chains.free panel - Serum
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(44816559) Phosphatidylethanol [Mass/volume] in Blood
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(3012110) Lysozyme [Mass/volume] in Serum or Plasma
0
7
0.00
0.00
0.0
2.3
—
10.5
—
0
7
(36305247) Microscopic observation [Identifier] in Isolate by Gram stain
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
(3042111) Morphology [Interpretation] in Bone marrow Narrative
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
(3046524) Influenza virus A Ag [Presence] in Nasopharynx by Immunoassay
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
(3006093) Chlamydia trachomatis DNA [Presence] in Specimen by NAA with probe detection
0
5
0.00
0.00
0.0
4.0
—
—
—
0
0
(3021788) Differential panel - Synovial fluid
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(1616796) Gas panel - Central venous blood
0
5
0.00
0.00
0.0
2.4
—
—
—
0
0
(3025941) Bacteria identified in Stool by Culture
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
(3042194) Human metapneumovirus RNA [Presence] in Specimen by NAA with probe detection
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
(3037551) Cancer Ag 125 [Units/volume] in Serum or Plasma
0
6
0.00
0.00
0.0
1.3
—
168.8
—
0
6
(36033641) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Rapid immunoassay
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
(42868544) Hantavirus puumala IgM Ab [Presence] in Serum or Plasma by Immunofluorescence
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(3002482) Mycoplasma pneumoniae DNA [Presence] in Specimen by NAA with probe detection
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(36032419) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Immunoassay
0
6
0.00
0.00
0.0
1.8
—
—
—
0
0
(3039443) Prostate specific Ag panel - Serum or Plasma
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
(3027315) Oxygen [Partial pressure] in Blood
0
6
0.00
0.00
0.0
1.3
—
8.1
—
0
6
(3017895) Helicobacter pylori Ab [Units/volume] in Serum
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
(3037756) Immunofixation for Serum or Plasma
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
(3023183) Ammonium ion [Moles/volume] in Plasma
0
5
0.00
0.00
0.0
2.0
—
51.0
—
0
5
(3021901) Oxygen saturation in Capillary blood
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
(3004490) Bicarbonate [Moles/volume] standard in Capillary blood
0
9
0.00
0.00
0.0
4.6
—
23.8
—
0
9
(3013290) Carbon dioxide [Partial pressure] in Blood
0
6
0.00
0.00
0.0
1.3
—
5.1
—
0
6
(3010421) pH of Blood
0
6
0.00
0.00
0.0
1.5
—
7.4
—
0
6
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: CD2_INSITU_MELANOMA_EAR_EXALLC – Melanoma in situ of ear and external auricular canal
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).